Ipamorelin

Quick Facts

Introduction

Ipamorelin is a synthetic pentapeptide belonging to the growth-hormone-releasing peptide (GHRP) family — compounds that mimic ghrelin to stimulate growth-hormone secretion. In research settings it is distinguished by its selectivity: it is associated with a clean growth-hormone pulse while reportedly leaving cortisol and prolactin largely unaffected, a contrast with earlier members of its class.

Ipamorelin is most often studied alongside GHRH analogues such as CJC-1295, because the two classes act through different receptors and complementary pathways. Where a GHRH analogue tells the pituitary 'release growth hormone,' a ghrelin-mimetic amplifies and shapes that release — a pairing that is one of the central concepts in secretagogue research.

This profile covers what Ipamorelin is, its ghrelin-receptor mechanism, the selectivity that defines it, the secretagogue research it appears in, and how it compares with related compounds such as CJC-1295, GHRP-2, and GHRP-6. Related compounds are catalogued in the peptide database.

What is Ipamorelin?

Ipamorelin is a selective growth-hormone secretagogue — a five-amino-acid peptide engineered to activate the ghrelin (growth-hormone-secretagogue) receptor and trigger growth-hormone release. It was developed as a more selective alternative to earlier GHRPs, with the explicit research goal of stimulating growth hormone without the off-target hormonal effects those earlier compounds produced.

Its small size and water solubility make it straightforward to handle. In the research literature, the recurring descriptor is selectivity: Ipamorelin is characterized as producing a growth-hormone pulse comparable to other GHRPs while reportedly having minimal impact on cortisol and prolactin, two hormones that earlier secretagogues tended to raise.

Molecular and structural characteristics

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) incorporating non-natural and D-amino acids that improve receptor selectivity and metabolic stability. These engineered residues are central to its defining property: they shape its binding so that it activates the ghrelin receptor without the broader endocrine activity of less selective GHRPs.

Mechanism of action

Ipamorelin acts as an agonist at the growth-hormone-secretagogue receptor (GHS-R) — the receptor for the natural hormone ghrelin. Activating this receptor on the pituitary stimulates growth-hormone release, and it does so through a pathway distinct from that of GHRH. This is why Ipamorelin and GHRH analogues are described as complementary rather than redundant.

The property that sets Ipamorelin apart is its selectivity for growth-hormone release. Earlier GHRPs activated their receptor in a way that also raised cortisol and prolactin; Ipamorelin is reported to produce a comparable growth-hormone pulse with minimal effect on those hormones. In research terms, it is studied as a 'cleaner' probe of the ghrelin-receptor pathway.

The most-discussed application of this mechanism is combination with a GHRH analogue such as CJC-1295. Because GHRH and ghrelin receptors sit on different signaling pathways, co-stimulation is studied for a synergistic growth-hormone response — a larger, coordinated pulse than either agent yields alone. This synergy is a recurring theme across the secretagogue literature.

• Agonism at the ghrelin / GHS receptor on the pituitary.
• Stimulation of pulsatile growth-hormone release.
• Selective action with minimal reported cortisol/prolactin effect.
• Synergy with GHRH analogues via complementary pathways.

Growth-hormone secretagogue research

Ipamorelin's research is centered on its role as a selective secretagogue. Comparative studies within the GHRP family examine how its hormonal profile differs from earlier compounds, with the recurring observation that it produces growth-hormone release while sparing the cortisol and prolactin responses that limited the usefulness of its predecessors as clean research tools.

A second major theme is the GHRH + GHRP combination model. Pairing Ipamorelin with a GHRH analogue is studied as a way to interrogate the two arms of growth-hormone control simultaneously, and the synergistic pulse this produces is one of the most-cited concepts connecting it to CJC-1295 and, more broadly, to the GH-axis work surrounding Tesamorelin.

Comparison: Ipamorelin vs GHRP-2 vs GHRP-6

Ipamorelin is most often compared with the earlier GHRPs GHRP-2 and GHRP-6. All three are ghrelin-mimetics that stimulate growth-hormone release, but they differ most in selectivity — specifically in how much they affect cortisol, prolactin, and appetite.

Where a GHRP is paired with a GHRH analogue, Ipamorelin's selectivity is often the reason it is chosen over GHRP-2 or GHRP-6. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Ipamorelin is a short-acting secretagogue, with a half-life typically described on the order of about two hours in the research literature. This brevity is consistent with its mechanism: it produces a discrete growth-hormone pulse rather than a sustained elevation, which is part of why it is studied as a tool for probing pulsatile release.

As with other peptides in this library, half-life figures should be treated as research observations that depend on study conditions. The short duration is the key interpretive feature: effects are pulse-like and time-limited rather than continuous.

Reconstitution and handling considerations

Ipamorelin is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentration is chosen so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Choose a working concentration that keeps research volumes reproducible.
• Protect from light and excess warmth.

Storage considerations

Lyophilized Ipamorelin is most stable frozen at −20 °C, away from light and moisture. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window, avoiding repeated freeze–thaw cycles. Aliquoting reduces how often a given solution is cycled.

Research limitations

Ipamorelin is a research compound. While its receptor biology and selectivity are comparatively well characterized within the GHRP family, much supporting data are preclinical or from limited clinical work, and reported effects are dose- and design-dependent. It is described here strictly for research reference.

• Evidence base is largely preclinical and limited clinical.
• Selectivity claims are relative to earlier GHRPs.
• Reported effects are dose- and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.Source
2. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition. Transl Androl Urol. 2020.Source